Cargando…

Druggable Targets of Squamous Cell Lung Cancer

Knowledge of molecular pathogenesis of non-small cell lung cancer has increased remarkably and changed the principles of treatment, especially during the past decade. These advancements have been limited mainly to adenocarcinoma of the lung. Recently, genetic alterations in squamous cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kim, Cheol Hyeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Tuberculosis and Respiratory Diseases 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884109/ https://www.ncbi.nlm.nih.gov/pubmed/24416052 http://dx.doi.org/10.4046/trd.2013.75.6.231

Ejemplares similares

Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma
por: Kordbacheh, Farzaneh, et al.
Publicado: (2021)

Druggable Drivers of Lung Cancer
por: Fawdar, Shameem, et al.
Publicado: (2013)

Cysteine metabolic circuitries: druggable targets in cancer
por: Bonifácio, Vasco D. B., et al.
Publicado: (2020)

Promising Druggable Target in Head and Neck Squamous Cell Carcinoma: Wnt Signaling
por: Aminuddin, Amnani, et al.
Publicado: (2016)

KRAS: A Druggable Target in Colon Cancer Patients
por: Negri, Francesca, et al.
Publicado: (2022)

Mitochondrial Potassium Channels as Druggable Targets
por: Wrzosek, Antoni, et al.
Publicado: (2020)

Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment
por: Mio, Catia, et al.
Publicado: (2019)

Intestinal Enteroendocrine Cells: Present and Future Druggable Targets
por: Atanga, Roger, et al.
Publicado: (2023)

Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?
por: Choi, Seul-Ki, et al.
Publicado: (2019)

The Discovery of Druggable Anti-aging Agents
por: Yalcin, Gulperi, et al.
Publicado: (2020)

Druggable genetic targets in endometrial cancer
por: Lehrer, Steven, et al.
Publicado: (2022)

Toxoplasmosis: Current and Emerging Parasite Druggable Targets
por: Hajj, Rana El, et al.
Publicado: (2021)

Novel Biomarkers and Druggable Targets in Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018)

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
por: Fois, Sara S., et al.
Publicado: (2021)

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
por: Nakhjavani, Maryam, et al.
Publicado: (2019)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects
por: Weng, Hao-Jui, et al.
Publicado: (2022)

Richter Syndrome: From Molecular Pathogenesis to Druggable Targets
por: Mouhssine, Samir, et al.
Publicado: (2022)

The Druggable Pocketome of Corynebacterium diphtheriae: A New Approach for in silico Putative Druggable Targets
por: Hassan, Syed S., et al.
Publicado: (2018)

Data-driven analysis and druggability assessment methods to accelerate the identification of novel cancer targets
por: Beis, G., et al.
Publicado: (2022)

A receptor-mediated landscape of druggable and targeted nanomaterials for gliomas
por: Di Filippo, Leonardo Delello, et al.
Publicado: (2023)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

NF-κB: A Druggable Target in Acute Myeloid Leukemia
por: Di Francesco, Barbara, et al.
Publicado: (2022)

An outlook on potential protein targets of COVID-19 as a druggable site
por: Noori, Rubia, et al.
Publicado: (2022)

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
por: Sincere, Nuwayo Ishimwe, et al.
Publicado: (2023)

Phenomic Microglia Diversity as a Druggable Target in the Hippocampus in Neurodegenerative Diseases
por: Lana, Daniele, et al.
Publicado: (2023)

Endoplasmic Reticulum Stress and Cancer: Could Unfolded Protein Response Be a Druggable Target for Cancer Therapy?
por: Bonsignore, Gregorio, et al.
Publicado: (2023)

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
por: Montor, Wagner Ricardo, et al.
Publicado: (2018)

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
por: Amodio, Nicola, et al.
Publicado: (2018)

An integrated structural proteomics approach along the druggable genome of Corynebacterium pseudotuberculosis species for putative druggable targets
por: Radusky, Leandro G, et al.
Publicado: (2015)

Drug Normalization for Cancer Therapeutic and Druggable Genome Target Discovery
por: Jiang, Guoqian, et al.
Publicado: (2015)

New Insights Into DNA Helicases as Druggable Targets for Cancer Therapy
por: Datta, Arindam, et al.
Publicado: (2018)

Integrated genomic analysis to identify druggable targets for pancreatic cancer
por: Mugiyanto, Eko, et al.
Publicado: (2022)

RORγ Structural Plasticity and Druggability
por: Huang, Mian, et al.
Publicado: (2020)

Druggable Transient Pockets in Protein Kinases
por: Umezawa, Koji, et al.
Publicado: (2021)

Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites
por: Merritt, Christopher, et al.
Publicado: (2014)

Network motifs modulate druggability of cellular targets
por: Wu, Fan, et al.
Publicado: (2016)

Druggable targets and therapeutic development for COVID-19
por: Duan, Xiaohua, et al.
Publicado: (2022)

IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants
por: Saggini, Andrea, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s4mbumu1qp1qdadr11106klufe